Background It has been reported that infants born by Caesarean
delivery, type of feeding, gestational age at birth, birthing environment and antibiotic use. 3 Compared to vaginally-born infants, infants delivered by Caesarean section had lower numbers of bifidobacteria and Bacteroides, but were found to be more often colonized with Clostridium difficile (C. difficile). 4 Formula-fed infants were more often colonized with Escherichia coli, C. difficile, Bacteroides and lactobacilli than infants who were breastfed. Hospitalization and prematurity were reportedly associated with higher prevalence and counts of C. difficile was associated with lower numbers of bifidobacteria and Bacteroides. 3 In the mammalian large intestine, there are
It has been well recognized that gut microbiota have an effect on host physiology. In addition, increasing evidence suggests that intestinal microbiota play an essential role in postnatal development of the immune system. 5 Several studies have investigated the effects of Caesarean section delivery on the development of allergic disease during the first years of life. A metain children who had been delivered by Caesarean section. 6 Also, a systematic review showed evidence that the risk of developing IgE-mediated sensitization to food allergens was increased among children delivered by Caesarean section. Furthermore, Caesarean delivery was indicated to be an additional risk factor for wheezing and allergic sensitization to food allergens in infants up to 2 years of age. 8 The FAO and WHO referred to probiotics as "live microorganisms which, when consumed in an Allergy prevention by way of probiotic administration to change infantile gut microbiota was first reported et al., who also showed that supplementation with Lactobacillus rhamnosus GG resulted in a reduction in atopic eczema persisting to 5 at high risk for allergies, pregnant mothers received probiotic mixtures consisting of two lactobacilli, Bifidobacterium breve, and a propionibacterium. From birth to 6 months, their infants received the same probiotics as well as a galacto-oligosaccharide atopic disease was observed in supplemented infants.
Although the probiotic supplementation did not extend an allergy-preventative effect to 5 years of age in the overall study group, it did confer protection to IgE-associated allergic disease in Caesarean-delivered children.
ate the impact of probiotic B. lactis supplementation on gut microbiota of babies born in two developing countries. More specifically, the effect of B. lactis supplementation in vaginally-delivered and Caesareandelivered infants was assessed by B. lactis presence and and 2 months of age. We also investigated the effect of B. lactis supplementation on growth, morbidity, and immune markers observed in these infants.
Methods
An open, non-randomized, controlled, parallel-group trial was carried out in two centers in Indonesia and Healthy infants delivered by Caesarean section or University Medical School, Bandung, Indonesia, or Khon Kaen University Medical School, Thailand. Inclusion criteria were maximum age of 2 weeks at be compliant, and having informed consent from a legal representative. Approval was obtained from Medical School, Bandung, Indonesia and Khon Kaen University, Khon Kaen, Thailand. Infants were predominantly breast fed for 2 weeks, followed by formula supplementation/mixed feeding of at least illness, significant pre-natal and/or post-natal disease, immunocompromised mothers, parents with a history of allergies, who received antibiotics at the time of enrollment, could not be expected to comply with the feeding regimen, or already participated in another clinical trial. who received breast milk and NAN 1® formula (Nestlé Nutrition, Indonesia) supplemented with probiotics (Bifidobacterium lactis the control group, who received breast milk and NAN 1® formula without probiotics. Both NAN 1® products were specifically formulated for the formula was administered orally, in accordance with the manufacturer's instructions.
Within each of these groups, approximately half of the infants were born by Caesarean section and half by vaginal delivery. A required minimum sample size levels of fecal bifidobacteria between the two study treat population (ITT) consisted of all infants who received the study formulations and provided any pertinent data. Given the non-randomized nature the product received. The per-protocol population (PP) consisted of infants in the ITT population who adhered to all protocol requirements without any included: hospitalization and/or serious adverse reactions during the study period, introduction of prohibited treatment/medication during the study period, and non-compliance and/or being off study formulations during the study period.
The primary outcomes of the study were presence of B. lactis and bifidobacteria counts in the stool of supplemented infants born by Caesarean section or vaginal delivery, compared to non-supplemented -ary outcomes were growth, morbidity, and levels of of age.
The presence of B. lactis in stool samples was determined by real time PCR using bifidobacteria specific primers. For analysis purposes, stool samples with undetected B. lactis were considered as 'absent'. Presence or absence of B. lactis in the stools of test and control groups was compared using chi square test. A logistic regression analysis was performed to assess the effect of probiotic supplementation, allowing for the mode of birth. Fecal bifidobacteria (cells/g) were measured by quantitative real-time PCR using bifidobacteria-specific primers, as described previously. and 2-month time points. For analysis purposes, bifidobacteria counts below the detection limit were set to the lower value of the detection limit 6 cells/g). Counts were log transformed and the resulting data assessed for normality. The nonparametric Mann-Whitney test was used to compare the test and control groups. Given the exploratory nature of the hypotheses studied, no correction of significance level was employed. Subsequently, all P The effect of B. lactis supplementation on growth was measured by progression of weight, recumbent length/height, and head circumference at the time Infants were weighed without clothing on electronic scales. In each of the study centers, the same scale was used for all infants at all visits. Throughout the study, the electronic weighing scales were calibrated in accordance with the manufacturer's recommendations. If duplicate measurements did
The individual measurements and the final mean of one set of measurements were recorded. Recumbent using a standardized length board. At least two people were present to maintain proper body alignment and full body extension with feet flexed. If the infant was able to stand with its full body extended, the height was taken. Head circumference was measured to the coated measuring tape. The measurement was taken approximately 2.5 cm above the eyebrows, directly over the largest circumference of the skull. If duplicate measurements were not within 2 mm, a second set of two measurements was obtained. The individual head circumference measurements and the final mean of one set of measurements were recorded.
Morbidity, which was defined as upper respiratory infections, diarrhea, use of antibiotics, or the presence of fever, was assessed at each visit from enrollment to 2 months. These illnesses were recorded by parents in a diary, reviewed by investigators following each scheduled visit, and recorded as adverse events. Medication was noted by the parents in the diary and consolidated by the investigators in the Concomitant dropped out during the study, with similar proportions groups. The most common reasons for dropping out were: a delay in the passing of stool creating difficulties to adhere to all protocol requirements without any in the control group. Within the PP population test and 35 were delivered vaginally. Within the control group, 26 were delivered by Caesarean section and 32 were born vaginally. demographic and baseline physical characteristics were similar between the test and control groups. The of 8 was similar for both groups. The mean maternal (SD 5.8) years in the control group, while the mean B. lactis was detected in stool samples at a significantly higher frequency in the test group (B. lactis supplemented) than in the control group (P< (Table 1) .
When both the treatment type and mode of birth were considered, we found that the frequency of B. lactis detection was significantly higher in supplemented Medication section of the case report form. The number of times the infants were seen at any health care facility in the period between scheduled visits was also documented. At each visit the mother/caregiver was asked about interim health problems. Diarrhea was defined as having three or more unformed stools as being separated from another diarrhea episode by at least three diarrhea-free days. Fever was defined as a baby's axillary temperature above 38°C, reaching 38.5°C at least once during a 24 hour period.
Analyses of the immune markers interleukin (IL)-Cesarean section enrolled in the Indonesian center ELISA kits as per the manufacturer's instructions. Stool Immunoglobulin (Ig)-A was also measured in a analyses were performed at 2 months in a subsample of using an IMMUNO-TECH Human IgA ELISA Kit (ZeptoMetrix®) as per manufacturer's instructions. An adverse event was defined as any untoward the supplemented or non-supplemented formula product and included illnesses, signs or symptoms occurring or worsening, abnormal laboratory findings mother/caregiver contacted the investigator or their given medical direction. An adverse event may or from the study. Any adverse event occurring during the study was reported and documented whether or not it was considered to be non-serious, serious, or related/unrelated to the treatment. The following information was recorded: description of the adverse event (including duration, frequency, intensity, and seriousness), action taken, outcome, sequelae, and relationship to the formula.
Results
infants born by either Caesarean section or vaginal delivery compared to non-supplemented infants, both Table 2 ). Logistic regression analysis revealed a strong positive effect of B. lactis supplementation on the detection of B. lactis in the stool. An odds ratio of that infants given the B. lactis times more likely to have stool positive for B. lactis when compared to infants given formula without the probiotic.
The geometric mean of bifidobacteria (cells/g) measured in the stool did not significantly differ month or the 2 month time points (Table 3) .
When the treatment type and mode of birth were considered, we found that infants born by Caesarean section who received the B. lactis supplement had a sigthan those born by Caesarean section who received at the end of the second month there was no longer a significant difference in bifidobacteria levels between these two groups. The stool bifidobacteria levels of infants born vaginally who were supplemented with B. lactis probiotic were not significantly different at either time point to levels measured in vaginally-born non-supplemented infants ( Table 4) .
Although not statistically significant, a trend for higher mean body weight and head circumference was observed in infants from the test group compared mean gain in head circumference from the first to the second month was 4.63 (SD 2.83) cm in the control group. Spearman's coefficient correlation test revealed a positive correlation between body length * Chi square test ** Only subjects in Indonesia had stool samples collected at 1 month; all subjects in the PP population had stool samples collected at 2 months Table 5 ). No serious morbidity was encountered by infants in either the test or control groups during this study (Table 6) .
23, or TGF-analyzed in blood samples taken from
were significantly different between the control and 
Discussion
To assess the effects of B. lactis probiotic-supplemented formula, we conducted an open, non-randomized, placebo-controlled, 2-treatment, parallel-group trial of healthy babies born by Caesarean section born in Indonesia and Thailand were assigned to supplemented with B. lactis probiotics, or the control formula. The primary endpoint of the study was the presence of B. lactis in the stool and bifidobacteria count, measured at 2 months of age. Measurements the Indonesian study population. Stool B. lactis detection and bifidobacteria levels were consistent with previously published study. B. lactis detection in the stool was significantly more -bination of breast milk and probiotic-supplemented formula compared to those who received breast milk B. lactis Table 1 ). B. lactis detection rates in infants who received the probiotic--month ( Table 2 ). These differences were still observed after 2 months. B. lactis detection in the test group Table  1 ), while B. lactis detection in infants who received and vaginal delivery, respectively ( Table 2) .
Bifidobacteria levels in stool samples were not significantly different between the test and control points (Table 3) . Similarly, the level of bifidobacteria in the stools of infants who received probiotics was not different between Caesarean-born infants and those born by vaginal delivery ( Table 4) . A significant difference was, however, observed between probioticsupplemented and non-supplemented infants born bifidobactera levels were significantly higher in Caesarean-born infants who received probiotics at the 2 month time point. These results suggest that the mode of delivery impacts the composition of intestinal microbiota soon after birth. Intestinal microbiota after Cesarean delivery is characterized by an absence of bifidobacteria species. Vaginallydelivered neonates, even if they showed individual microbial profiles, were characterized predominantly by groups such as B. longum and B. catenulatum. This effect may partly explain the lack of difference in bifidobacteria levels observed between the test and control vaginally-delivered populations, particularly contributing factor is the previously documented bifidogenic effect of breast milk. All infants in this study were on a mixed-feeding regimen. As such, the breastfeeding component likely affected bifidobacteria levels. The microbiota colonization of infants born vaginally is generally dominated by bifidobacteria and lactobacilli strains, while C. difficile and E. coli are found in small amounts. Although there are many beneficial bacterial species in the intestine, such as L. acidophyllus, L. casei, L. salivarius, B. longum, and B. bifidum, the bifidobacteria group has been reported as the predominant microbiota and is known to have a role in maintaining the gut ecology. Previous research has compared bifidobacteria levels in term infants who were fed formula milk containing bifidobacteria, infants who were fed formula milk without bifidobacteria, and exclusively breastfed infants. Stool bifidobacteria levels of infants fed supplemented formula were found to be similar to those of exclusively breastfed infants, but significantly higher than the levels measured in infants who were fed non-supplemented formula milk.
A study reported that administration of B. lactis number of bifidobacteria and reduced the number of enterobacteria and clostridia, but did not reduce the colonization of organisms which were resistant to antibiotics. A recent review also suggested that B. lactis supplementation has the potential to increase the total number of bifidobacteria in feces and to reduce enterobacteria and clostridia. A significantly reduced intestinal permeability in preterm infants receiving Bifidus BL (B. lactis) supplementation has also been reported.
The baseline anthropometry data of the test and control groups was similar. At the first and second month, the mean weight and mean head circumference were consistently higher in the probiotic-supplemented group. A statistically significant positive correlation between body length and bifidobacteria time point. Overall, anthropometry results suggested that formula supplemented with B. lactis probiotic may assist infant growth, though these results were generally not statistically significant.
The immune markers measured were not significantly different between the test and control groups. It is noteworthy to mention that all immune parameters were measured in infants who were breastfed for at least the first two weeks of life. This certainly impacted the IgA outcomes and likely also affected the cytokine profiles. In this context, supplementation of breastfeeding with formula (with or without B. lactis probiotics) did not add benefits beyond breastfeeding alone. Although it is possible that a benefit of B. lactis supplementation may be seen in infants who encounter an early cessation of breast feeding, the duration of this study may have been too brief to see such an effect. A recently published study investigated the effect of B. lactis supplementation on intestinal antibody responses in 6-week-old infants. Infants were fed either a whey-based starter formula or the same formula supplemented with a B. lactis a period of 6 weeks. Interestingly, infants born by Caesarean section who received the probiotic had enhanced immune responses to poliovirus and rotavirus vaccines, as measured by increases in fecal anti-rotavirus-and anti-poliovirus-specific IgA, when compared to Caesarean-born infants who received non-supplemented formula.
In conclusion, results of this study suggest that infants, in particular those born by Caesarean section, may benefit from formula supplementation with B. lactis probiotics. Although probiotic supplementation do not appear to affect the levels of immune markers measured, it may be interesting in future to investigate possible correlations between immune parameters and B. lactis presence.
